Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
Primary: This study is being conducted to evaluate if AVE1625 is safe and tolerated in
patients with Alzheimer's disease that is not too severe. There is also evaluation of whether
patients who take the study medication improve compared to patients who take a placebo (sugar
pill).
Secondary:The study will also evaluate the blood levels of the study medication, AVE1625 in
patients who join the study.